Exelixis, Inc. (NASDAQ: EXEL) will release its fourth quarter and full year 2013 financial results on Thursday, February 20, 2014 after the markets close. The announcement will be followed by a live webcast at 5:00 p.m. EST/ 2:00 p.m. PST. During the webcast, Exelixis management will discuss the Company's financial results, financial outlook and development program and plans for cabozantinib, and also provide a general business update. The webcast may be accessed in the Event Calendar page under Investors & Media at www.exelixis.com. An archived replay of the webcast will be available on the Event Calendar page under Investors & Media at www.exelixis.com and via phone until 11:59 p.m. EST on March 20, 2014. Access numbers for the phone replay are: 888-286-8010 (domestic) and 617-801-6888 (international); the passcode is 59600043. About Exelixis Exelixis is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on COMETRIQ® (cabozantinib). Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at www.exelixis.com. Exelixis, the Exelixis logo, and COMETRIQ are registered U.S. trademarks.